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Abstract
Malignant peripheral nerve sheath tumor (MPNST) is a rare tumor that is 
one of the most aggressive malignant lesions in the head and neck area. 
The majority of MPNSTs arise de novo or from malignant transformation of 
pre-existing neurofibromas, particularly in individuals with neurofibroma-
tosis type 1 (NF1). However, solitary neurofibromas without an associa-
tion with NF1 seldom recur after excision and rarely develop malignant 
changes. We present a 70-year-old man with a recurrent neurofibroma of 
the right side of the neck which transformed to low-grade MPNST after 
multiple excisions. The patient had no cutaneous features or family history 
consistent with NF1. Progression from a recurrent sporadic neurofibroma 
to malignancy is an extremely rare event and we found only two case reports 
in the literature. Any recurrent mass at the site of an excised neurofibroma 
or a rapidly enlarging, painful swelling of antecedent lesions should prompt 
consideration of MPNST. [Tzu Chi Med J 2010;22(4):195–199]
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1. Introduction
Malignant peripheral nerve sheath tumors (MPNSTs) are 
uncommon and highly aggressive soft tissue sarcomas 
with high rates of local recurrence and distant metas-
tasis. MPNSTs can arise de novo as isolated malig-
nancies, whereas approximately half of these tumors 
develop through malignant transformation of pre-
existing neurofibromas in patients with neurofibroma-
tosis type 1 (NF1), also known as von Recklinghausen’s 
neurofibromatosis [1]. Solitary neurofibromas without 
an association with NF1 have a low recurrence rate 
after excision and very rarely become malignant [2]. 
Our patient had multiple recurrences of a neck mass 
which was treated with surgical excision. The patho-
logic diagnosis in each recurrence was neurofibroma, 
but malignant transformation to MPNST was noted in 
the last pathological exam. The clinical presentation 
of malignant alteration in a recurrent neurofibroma 
without association with NF1 is extremely rare. We 
found only two similar case reports in the English liter-
ature (Table 1) [3,4].
196 TZU CHI MED J  December 2010  Vol 22  No 4
2. Case report
A 70-year-old man was admitted to our department 
with a 1-month history of a progressively enlarging, 
painful swelling on the upper right side of his neck. In 
1995, he had undergone surgical resection of a neuro-
fibroma in the right cervical region. The tumor recurred 
at the previous operation site. Consequently, four 
more neck surgeries were done over the next 9 years. 
All pathologic diagnoses were diffuse neurofibroma 
(Fig. 1). When the patient presented to our department, 
a recurrent, solid, and ill-defined mass tightly encased 
by skin was palpated on examination. Computed to-
mography disclosed a 5.5 × 5 × 2 cm soft tissue mass 
posterior to the sternomastoid muscle (Fig. 2).
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Fig. 1 — The tumor is composed of proliferated slender 
spindle cells with wavy nuclei, growing in fascicles in a 
fibrotic stroma. Low cellularity and only mild nuclear 
atypia are noted.
Fig. 2 — Axial computed tomography of the head and neck 
shows an inhomogeneous mass (arrow) with ill-defined 
margins involving the right upper cervical area.
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The tumor was completely excised and microscopic 
examination revealed a low-grade MPNST arising within 
a neurofibroma, with areas of the lesion showing the 
typical features of a neurofibroma but also focal areas 
of increased cellularity with moderately to markedly 
pleomorphic cells, common mitotic activity and atyp-
ical mitotic figures. Immunohistochemically, the tumor 
cells were positive for S-100 protein (polyclonal rabbit; 
Dako Denmark A/S, Glostrup, Denmark) (Fig. 3), but 
negative for cytokeratin (AE1/AE3; Leica Biosystems, 
Newcastle Upon Tyne, UK), desmin (monoclonal mouse, 
D33; Dako Denmark A/S), epithelial membrane antigen 
(monoclonal mouse, E29; Dako Denmark A/S), smooth 
muscle actin (monoclonal mouse, 1A4; BioGenex 
Laboratories Inc., San Ramon, CA, USA), and CD34 
(QBEnd/10; Leica Biosystems). The patient had no 
history of radiotherapy of the head and neck region 
or physical features of NF.
Postoperatively, the patient received 7020 cGy of 
adjuvant radiotherapy. Eighteen months following di-
agnosis and surgery, the patient began to complain of 
submental swelling and progressive right-sided facial 
palsy. Magnetic resonance imaging demonstrated ex-
tensive tumor progression with invasion of the sub-
mental, right parotid and carotid space (Fig. 4). The 
patient underwent a right selective neck dissection 
with in continuity total parotidectomy, and histological 
examination confirmed the recurrence. The patient 
was lost to follow-up 2 months after the operation.
3. Discussion
MPNSTs have been reported to originate throughout 
the body, but the lower extremities and trunk are the 
most frequently involved areas. Although approxima-
tely 25% of all neurofibromas are found in the head 
and neck region, fewer than 10% of MPNSTs affect 
this anatomic area. In this region, the neck is most 
frequently (40–60%) involved [2,5].
MPNSTs have a variety of origins. A majority (25–
50%) originate in patients with NF1, presumably from 
an antecedent neurofibroma. The remaining cases 
are tumors arising de novo or within neurofibromas 
in patients without the stigmata of NF1 [6]. It is esti-
mated that 8–13% of NF1-associated neurofibromas 
eventually become malignant, usually after a latency 
of 10–20 years. Irradiation and long-standing plexi-
form types have been recognized as risk factors [7,8]. 
Pain, a change in texture, increase in size and neuro-
logical deficits should increase suspicion of malig-
nancy [9]. However, the majority of neurofibromas in 
the head and neck region appear as isolated lesions 
without association with NF1. The clinical behavior 
of isolated neurofibromas is characterized by a be-
nign course with a low frequency of recurrence after 
A B
Fig. 3 — (A) Area of spindle cells with increased cellularity, moderate to marked cellular pleomorphism, common 
mitotic activity, and hyperchromatic nuclei. (B) Focal S-100 immunoreactivity in the MPNST.
Fig. 4 — Axial magnetic resonance imaging shows infil-
trative lesions (arrow) involving the right parotid and 
carotid spaces.
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surgical excision. Malignant change is rare and diffi-
cult to detect; hence, the incidence is unknown [2]. 
A search of the literature revealed two well-documented 
case reports [3,4] of MPNST that transformed from a 
recurrent solitary neurofibroma in patients without 
NF1; our case is the third (Table 1). Clinical and histo-
logical caution should be exercised in the presence 
of multiple recurrences of isolated neurofibromas 
which may signify malignant change.
On computed tomography and magnetic reso-
nance imaging, a large tumor (> 5 cm), heterogeneity, 
ill-defined margins, invasion of fat planes, and evi-
dence of aggressiveness should raise suspicions of 
MPNST. However, differentiation of benign tumors from 
MPNSTs is often difficult with these tools [1,10].
Histologically, the distinction between neurofibro-
mas and low-grade MPNSTs is difficult because there is 
a continuum between these two lesions. Generalized 
nuclear atypia, increased cellularity and usually low 
levels of mitotic activity may help to establish the 
diagnosis of low-grade MPNSTs arising within a neu-
rofibroma [11]. The immunoreactivity of S-100 pro-
tein in MPNSTs tends to be focal and patchy, not strong 
and diffuse as seen in neurofibromas and schwan-
nomas. These patterns of immunopositivity may be 
useful in distinguishing benign nerve sheath tumors 
from MPNSTs [12]. However, the expression of S-100 
protein is reduced or absent in some low-grade MPNSTs 
and in more than two-thirds of high-grade MPNSTs. 
A recent study reported that CD10 expression helps in 
distinguishing solitary, localized neurofibromas from 
NF1 cases and from atypical, plexiform and malignant 
cases, but further investigation is necessary [13]. The 
diagnosis of MPNST requires a combination of clinical 
information and histomorphological features with 
supportive immunostains.
Curative treatment of MPNSTs is difficult. Every ef-
fort should be made to perform en bloc resection with 
tumor-free margins [14,15]. A prophylactic neck dis-
section is not warranted because lymphatic spread is 
rare. Adjuvant radiotherapy is recommended whether 
tumor-free margins can be obtained or not. The role of 
systemic chemotherapy remains controversial [1,14].
The prognosis of MPNSTs of the head and neck 
is relatively poorer than that of the extremities and 
trunk, with documented 5-year survival rates from 
15% to 35% [14,15]. This difference is related mainly 
to a difference in local tumor control. Because of the 
great density of vital structures and unresectable 
areas in the head and neck, such as the skull base, 
internal carotid artery and cervical vertebrae, failure 
to perform adequate wide excision is common and 
generally associated with an unacceptably high local 
recurrence rate [14,16]. Even with negative surgical 
margins, up to 50% of MPNSTs recur locally, often on 
multiple occasions [15]. This marked tendency for 
local recurrence has been attributed to the ability of 
this tumor to infiltrate surrounding tissues and invade 
perineural areas. One year following adjuvant radio-
therapy, our patient had local recurrence with exten-
sion to the carotid space that made complete resection 
impossible.
In conclusion, MPNSTs tend to be under-recognized 
and initial diagnosis is hampered by the clinical, radio-
logical and histological similarity of MPNSTs to benign 
tumors. Our reported case and those in the literature 
show that close monitoring of patients with recurrent 
neurofibroma is merited as this feature may signify 
malignant transformation. The tendency to local re-
currence contributes to the poor prognosis of the 
neoplasm, especially in the head and neck region. 
The outcome is principally a function of local control 
by means of surgical resection.
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